Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.47 EUR | +3.08% | +1.93% | +32.14% |
05-28 | RevolKa Signs Master Service Agreement with Daiichi Sankyo | CI |
05-27 | AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 61.84 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+32.14% | 66.06B | - | ||
+39.82% | 734B | C+ | ||
+32.57% | 591B | B | ||
-7.31% | 350B | C+ | ||
+14.23% | 315B | B- | ||
+0.86% | 276B | C+ | ||
+14.25% | 238B | B+ | ||
-6.30% | 204B | A+ | ||
+8.78% | 206B | B- | ||
+4.51% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4568 Stock
- D4S Stock
- Ratings Daiichi Sankyo Co., Ltd.